<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2071-8713-4845</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-4845</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Преимущества терапии сахарного диабетабазальным аналогом инсулина детемир (Левемир®)</article-title><trans-title-group xml:lang="en"><trans-title>Preimushchestva terapii sakharnogo diabetabazal'nym analogom insulina detemir (Levemir®)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ametov</surname><given-names>A S</given-names></name></name-alternatives><email xlink:type="simple">endocrin@mtu-net.ru</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Soluyanova</surname><given-names>T N</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>15</day><month>09</month><year>2011</year></pub-date><volume>8</volume><issue>3</issue><issue-title>№3 (2011)</issue-title><fpage>84</fpage><lpage>86</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ametov A.S., Soluyanova T.N., 2011</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="ru">Ametov A.S., Soluyanova T.N.</copyright-holder><copyright-holder xml:lang="en">Ametov A.S., Soluyanova T.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/4845">https://www.omet-endojournals.ru/jour/article/view/4845</self-uri><abstract/><trans-abstract xml:lang="en"/></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">International Diabetes Federation Atlas, 4th edition, 2009.</mixed-citation><mixed-citation xml:lang="en">International Diabetes Federation Atlas, 4th edition, 2009.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И. и др. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа» // Сахарный диабет. - 2011. - № 1. - С. 95-105.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И. и др. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа» // Сахарный диабет. - 2011. - № 1. - С. 95-105.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kurtzhals P. et al. // J Pharm Sci. - 1996. - № 85. - Р. 304-308.</mixed-citation><mixed-citation xml:lang="en">Kurtzhals P. et al. // J Pharm Sci. - 1996. - № 85. - Р. 304-308.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hermansen К., Fontaine P., Kukolja К.К. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy forpatients with type 1 diabetes // Diabetologia. - 2004. - № 47(4). - Р. 622-629.</mixed-citation><mixed-citation xml:lang="en">Hermansen К., Fontaine P., Kukolja К.К. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy forpatients with type 1 diabetes // Diabetologia. - 2004. - № 47(4). - Р. 622-629.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Standi E., Roberts A., Lang H., et al. The 12-month efficacy and safety of insulin detemirand NPH insulin in basal-bolustherapy for the treatment of type 1 diabetes // Diabetes Technology Therapeutics. - 2004. - № 6(5). - Р. 579-88.</mixed-citation><mixed-citation xml:lang="en">Standi E., Roberts A., Lang H., et al. The 12-month efficacy and safety of insulin detemirand NPH insulin in basal-bolustherapy for the treatment of type 1 diabetes // Diabetes Technology Therapeutics. - 2004. - № 6(5). - Р. 579-88.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Philis-Tsimikas A., Charpentier G., Per Clauson et al. Comparison of One-daily Insulin Detemir with NPH Insulin Added to a Regimen of Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes // Clinical Therapeutics. - 2006. - V. 28 (10). - Р. 1569-1581.</mixed-citation><mixed-citation xml:lang="en">Philis-Tsimikas A., Charpentier G., Per Clauson et al. Comparison of One-daily Insulin Detemir with NPH Insulin Added to a Regimen of Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes // Clinical Therapeutics. - 2006. - V. 28 (10). - Р. 1569-1581.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dornhorst A., et al. Safety and efficacy of insulin detmir in clinical practice: 14-week follow-up data from type 1 and 2 diabetes patients in the PREDICTIVE // European cohort Inte Journal of Clin Practice. - 2007.</mixed-citation><mixed-citation xml:lang="en">Dornhorst A., et al. Safety and efficacy of insulin detmir in clinical practice: 14-week follow-up data from type 1 and 2 diabetes patients in the PREDICTIVE // European cohort Inte Journal of Clin Practice. - 2007.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hollander P. et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basalbolus regimen with mealtime insulin aspart in patients with type 2 diabetes // Сд Ther. - 2008. - № 20(11). - Р. 1976-1987.</mixed-citation><mixed-citation xml:lang="en">Hollander P. et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basalbolus regimen with mealtime insulin aspart in patients with type 2 diabetes // Сд Ther. - 2008. - № 20(11). - Р. 1976-1987.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Verges B. et al. Long-acting insulin analogue therapy initiation and follow-up by healthcare practitioners in patients with T2DM uncontrolled with oral antidiabetic drugs: the LIGHT study. Novo Nordisk book of abstracts // EASD. - 2009; poster № 972.</mixed-citation><mixed-citation xml:lang="en">Verges B. et al. Long-acting insulin analogue therapy initiation and follow-up by healthcare practitioners in patients with T2DM uncontrolled with oral antidiabetic drugs: the LIGHT study. Novo Nordisk book of abstracts // EASD. - 2009; poster № 972.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hollander P. et al. Efficacy and safety of insulin detemir once-daily in combination with sitagliptin and metformin: the Transition™ randomised controlled trial // Diabetes, Obesity and Metabolism. - Published online, 3 December 2010.</mixed-citation><mixed-citation xml:lang="en">Hollander P. et al. Efficacy and safety of insulin detemir once-daily in combination with sitagliptin and metformin: the Transition™ randomised controlled trial // Diabetes, Obesity and Metabolism. - Published online, 3 December 2010.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
